✦ LIBER ✦

Morphologic and Immunophenotypic Markers as Surrogate Endpoints of Tamoxifen Effect for Prevention of Breast Cancer

✍ Scribed by Syed K. Mohsin; D. Craig Allred; C. Kent Osborne; Anatolio Cruz; Pamela Otto; Helen Chew; Gary M. Clark; Richard M. Elledge

Publisher: Springer US
Year: 2005
Tongue: English
Weight: 229 KB
Volume: 94
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-005-4896-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Benefit and projected cost-effectiveness

Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor–positive breast cancer

✍ Bruce E. Hillner 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 1 views

## Abstract ## BACKGROUND Women who have estrogen receptor (ER)‐positive disease with postmenopausal onset and who receive tamoxifen as standard adjuvant treatment constitute the largest subgroup of patients with breast cancer. Recent data from the ATAC (‘Arimidex, Tamoxifen Alone or in Combinatio

Validation of the use of C-2/C-16α estro

Validation of the use of C-2/C-16α estrogen metabolites as markers for the action of chemopreventive agents in the prevention of breast cancer

✍ H. Leon Bradlow; Daniel W. Sepkovic; Thomas Klug; Michael P. Osborne 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB

nin antibody is cytotoxic to malignant cells in vitro in concentrations of picograms/cell. In a 20-year study involving several hundred physicians and three independent laboratories in the U.S., and three hospitals and one laboratory in the U.K., we have found that the concentration of antimalignin